ATAI vs. IOVA

Last updated Apr 2, 2026

Compare and contrast key facts about Atai Life Sciences N.V. (ATAI) and Iovance Biotherapeutics, Inc. (IOVA).

Performance

ATAI vs. IOVA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Atai Life Sciences N.V. (ATAI) and Iovance Biotherapeutics, Inc. (IOVA). The values are adjusted to include any dividend payments, if applicable.

ATAI vs. IOVA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
ATAI Atai Life Sciences N.V.	-9.54%	207.52%	-5.67%	-46.99%	-65.14%	-60.77%
IOVA Iovance Biotherapeutics, Inc.	26.37%	-63.11%	-8.98%	27.23%	-66.53%	-22.96%

Fundamentals

Market Cap ATAI : $1.16B IOVA : $1.40B
EPS ATAI : -$2.72 IOVA : -$1.06
PS Ratio ATAI : 219.71 IOVA : 4.82
PB Ratio ATAI : 5.24 IOVA : 2.01
Total Revenue (TTM) ATAI : $4.09M IOVA : $263.50M
Gross Profit (TTM) ATAI : $3.08M IOVA : $256.22M
EBITDA (TTM) ATAI : -$113.05M IOVA : -$357.11M

Returns By Period

In the year-to-date period, ATAI achieves a -9.54% return, which is significantly lower than IOVA's 26.37% return.

ATAI

• 1D: 4.52%
• 1M: 0.54%
• YTD: -9.54%
• 6M: -28.85%
• 1Y: 198.39%
• 3Y*: 26.91%
• 5Y*: —
• 10Y*: —

IOVA

• 1D: -1.71%
• 1M: -8.97%
• YTD: 26.37%
• 6M: 56.11%
• 1Y: 6.15%
• 3Y*: -17.35%
• 5Y*: -36.04%
• 10Y*: -4.04%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ATAI vs. IOVA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATAI

ATAI Risk / Return Rank: 88
ATAI Sharpe Ratio Rank: 93
ATAI Sortino Ratio Rank: 91
ATAI Omega Ratio Rank: 87
ATAI Calmar Ratio Rank: 88
ATAI Martin Ratio Rank: 82

IOVA

IOVA Risk / Return Rank: 46
IOVA Sharpe Ratio Rank: 42
IOVA Sortino Ratio Rank: 53
IOVA Omega Ratio Rank: 53
IOVA Calmar Ratio Rank: 42
IOVA Martin Ratio Rank: 42

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ATAI vs. IOVA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Atai Life Sciences N.V. (ATAI) and Iovance Biotherapeutics, Inc. (IOVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ATAI	IOVA	Difference
Sharpe ratio Return per unit of total volatility	2.35	0.06	+2.30
Sortino ratio Return per unit of downside risk	2.97	0.96	+2.00
Omega ratio Gain probability vs. loss probability	1.36	1.13	+0.24
Calmar ratio Return relative to maximum drawdown	3.58	0.07	+3.51
Martin ratio Return relative to average drawdown	6.67	0.10	+6.58
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ATAI vs. IOVA - Sharpe Ratio Comparison

The current ATAI Sharpe Ratio is 2.35, which is higher than the IOVA Sharpe Ratio of 0.06. The chart below compares the historical Sharpe Ratios of ATAI and IOVA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ATAI	IOVA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.35	0.06	+2.30
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.40	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.05	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.35	-0.14	-0.21

Correlation

The correlation between ATAI and IOVA is 0.40, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

ATAI vs. IOVA - Dividend Comparison

Neither ATAI nor IOVA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ATAI vs. IOVA - Drawdown Comparison

The maximum ATAI drawdown since its inception was -94.77%, roughly equal to the maximum IOVA drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for ATAI and IOVA.

Drawdown Indicators

	ATAI	IOVA	Difference
Max Drawdown Largest peak-to-trough decline	-94.77%	-99.37%	+4.60%
Max Drawdown (1Y) Largest decline over 1 year	-48.06%	-54.41%	+6.35%
Max Drawdown (5Y) Largest decline over 5 years	—	-94.98%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-96.84%	—
Current Drawdown Current decline from peak	-81.40%	-97.83%	+16.43%
Average Drawdown Average peak-to-trough decline	-79.80%	-84.01%	+4.21%
Ulcer Index Depth and duration of drawdowns from previous peaks	25.79%	37.79%	-12.00%

Volatility

ATAI vs. IOVA - Volatility Comparison

The current volatility for Atai Life Sciences N.V. (ATAI) is 21.20%, while Iovance Biotherapeutics, Inc. (IOVA) has a volatility of 30.95%. This indicates that ATAI experiences smaller price fluctuations and is considered to be less risky than IOVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ATAI	IOVA	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.20%	30.95%	-9.75%
Volatility (6M) Calculated over the trailing 6-month period	53.28%	65.58%	-12.30%
Volatility (1Y) Calculated over the trailing 1-year period	85.32%	112.15%	-26.83%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	84.10%	90.77%	-6.67%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	84.10%	81.91%	+2.19%

Financials